ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3144-Malvern-Cabrini-Health,-Cabrini-Cancer-Care-Centre
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
48
trial(s) found.
NCT07746141
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-85738, Alone or in Combination With Other Antitumor Agents, in Patients With Advanced or Metastatic Solid Tumors With RAS Mutations (
BG-85738-101
)
pan-RAS inhibitor,undisclosed mechanism
Solid tumour
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT07713732
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors (
TLN-499-2601
)
Bcl-xL degrader
Bcl2 inhibitor
Neuroendocrine tumour
Pleural mesothelioma
Small-cell lung cancer
Synovial sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07535112
Advanced
Phase 1
Recruiting
Master Protocol: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BAY 3771249 as Monotherapy or Combination With Other Cancer Treatments in Participants With Solid Tumors Harboring a KRAS G12D Mutation. Substudy Protocol: An Open-label, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of BAY 3771249 as Monotherapy and in Combination With Cetuximab in Participants With Advanced/Metastatic Colorectal Adenocarcinoma Harboring a KRAS G12D Mutation (
23111-1
)
KRAS G12D inhibitor,OFF-state inhibitor
anti-EGFR monoclonal antibody
Colorectal adenocarcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT07486817
Advanced
Phase 2
Recruiting
Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations (
1479-0044
)
ERBB2 inhibitor,second generation
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07456046
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-003 Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation (
D3S-003-100
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT07414836
Advanced
Phase 1
Recruiting
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients With Selected Advanced Solid Tumors (
BG-C0979-101
)
anti-ADAM9 antibody-drug conjugate
Solid tumour
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07293351
Advanced
Phase 1 / Phase 2
Recruiting
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (
CA266-0008
)
bispecific PD-L1/VEGFA antibody
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4029 - Herston - Metro North Hospital and Health Service
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07277231
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia (
BGB-11417-304
)
BTK inhibitor
Bcl2 inhibitor
Chronic lymphocytic leukaemia
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT07226986
Radonc
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) (
CAMO959A12103
)
DNA-dependent protein kinase inhibitor
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07226349
Advanced
Phase 1
Recruiting
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors (
BG-75098-101
)
CDK2 inhibitor
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - One Clinical Research
NCT07221357
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (
CA266-0003
)
anti-VEGF monoclonal antibody
bispecific PD-L1/VEGFA antibody
Colorectal adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07213804
Advanced
Phase 3
Recruiting
FRAmework-01
: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-VEGF monoclonal antibody
Carcinoma
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
TAS
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT07174583
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer (
IDE849-001
)
anti-DLL3 antibody-drug conjugate
Small-cell lung cancer
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT07140900
Advanced
Phase 1
Recruiting
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
bispecific T-cell engager,STEAP1-targeting
Castrate-sensitive prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT07044336
Advanced
Phase 3
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) (
D6900C00003
)
anti-B7H4 antibody-drug conjugate
Endometrial cancer
NOT Neuroendocrine carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06973187
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (
BGB-16673-304
)
BTK PROTAC degrader
BTK inhibitor
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06855277
Radonc
Phase 3
Recruiting
A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (
AcTFirst
)
radioligand,PSMA-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06819735
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (
DOMISOL
, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)
anti-CCR8 monoclonal antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT06697184
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies. (
BGB-11417-108
)
Bcl2 inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5000 - South Australia - GenesisCare St Andrews Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6168 - Cooloongup - Rockingham Hospital
NCT06672185
Advanced
Phase 1
Recruiting
A Phase 1 Study of ARC101 in Advanced Solid Tumors (
ARC101-P1-101
)
bispecific T-cell engager,CLDN6-targeting
Solid tumour
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Cancer Research SA
NCT06659341
Advanced
Phase 1
Recruiting
Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors
SOS1-KRAS inhibitor
Colorectal adenocarcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
NCT06649708
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies (
HX044-I-01
)
unknown drug class
Cancer
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT06625593
Advanced
Phase 1
Recruiting
A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors (
BG-C137-101
)
anti-FGFR2b antibody-drug conjugate
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06598800
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (
BG-T187-101
)
trispecific EGFR/cMET/cMET antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06597721
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors (
ADCE-T02-001
)
anti-TF antibody-drug conjugate
Head and neck squamous cell carcinoma
Pancreatic adenocarcinoma
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06594926
Curative
Phase 2
Recruiting
Evaluating the Efficacy of Bipolar Androgen Therapy in Extending Metastasis-free Survival in Patients With M0 Castrate-resistant Prostate Cancer With PSA Progression But Not Radiological or Clinical Progression on Darolutamide (
WOMBAT
)
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit (TERMINATED)
ACT
2605 - Garran - The Canberra Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3677 - Wangaratta - Northeast Health Wangaratta
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06400485
Advanced
Phase 1
Recruiting
First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors (
AMT-676-01
)
anti-CDH17 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06380751
Advanced
Phase 3
Recruiting
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (
EvoPAR-BR01
)
PARP1-selective inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
NCT06326411
Advanced
Phase 1
Recruiting
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue
NST-628
Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
pan-RAF/MEK glue
Glioma
Melanoma
NOT Melanoma
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd (COMPLETED)
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06233942
Advanced
Phase 1
Recruiting
Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (
BG-C9074-101
)
anti-B7H4 antibody-drug conjugate
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (COMPLETED)
NCT05969041
Advanced
Phase 1
Recruiting
MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (
MYE-Symphony
)
Trop2-targeting lipid-nanoparticles
Cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05957536
Advanced
Phase 1
Recruiting
A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors. (
D3L-001-100
)
bispecific ERBB2/CD47 antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT05957081
Advanced
Phase 1
Recruiting
A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors (
MarkV-01
)
anti-PD-1 monoclonal antibody
anti-VISTA monoclonal antibody
Solid tumour
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4217 - Benowa - Pindara Private Hospital
NCT05939414
Radonc
Phase 3
Recruiting
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC) (
PSMA-DC
)
radioconjugate,PSMA-targeting
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05910827
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas (
HMBD-001-103
)
anti-EGFR monoclonal antibody
anti-ERBB3 monoclonal antibody,third generation
taxane
Squamous non-small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05906862
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-253, in Patients With Advanced Solid Tumors (
AMT-253-01
)
anti-MUC18 antibody-drug conjugate
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05785754
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (
DCSZ11-101
)
anti-CD93 monoclonal antibody
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2076 - Wahroonga - Sydney Adventist Hospital (WITHDRAWN)
2170 - Liverpool - Liverpool Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Townsville - Townsville University Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (WITHDRAWN)
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05725291
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors (
AMT-116-01
)
anti-CD44v9 antibody-drug conjugate
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05718895
Advanced
Phase 1
Recruiting
An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors (
CLINCH
)
anti-CLDN18.2 antibody-drug conjugate
Solid tumour
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
NCT05410145
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (
D3S-001-100
)
KRAS G12C inhibitor,OFF-state inhibitor
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04683250
Advanced
Phase 1 / Phase 2
Recruiting
Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities (
MARGARET
)
RET-selective inhibitor
Non-small cell lung cancer
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6009 - Nedlands - One Clinical Research
NCT04516447
Advanced
Phase 1
Recruiting
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer (
MUIR
)
WEE1 inhibitor
anti-VEGF monoclonal antibody
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
VIC
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (COMPLETED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12624000582550
Curative
Phase 2
Recruiting
Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (
WOMBAT
) - ANZUP 2201
antiandrogen,nonsteroidal,second generation
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3677 - Wangaratta - Northeast Health Wangaratta
QLD
4032 - Chermside - The Prince Charles Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12623000874617
Advanced
Phase 2
Recruiting
Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (
Biomarcer-2
)
anti-EGFR monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000307606
Advanced
Phase 1
Recruiting
A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of RX108-A Tablet in Patients with Locally Advanced or Metastatic Solid Tumors (
NP-105
)
sodium-potassium ATPase inhibitor
Solid tumour
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT06199908
Advanced
Phase 1
Unknown
First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors (
AMT-562-01
)
anti-ERBB3 antibody-drug conjugate
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT05462236
Advanced
Phase 2
Unknown
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (
AUM001-2001-MK3475-D65
)
MNK1/2 inhibitor
anti-PD-1 monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4217 - Benowa - Pindara Private Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (46)
Unknown (2)
Recruitment Country and State
VIC (48)
NSW (41)
QLD (25)
WA (21)
SA (17)
NZ (3)
ACT (3)
TAS (1)
Phase
Phase 1 (25)
Phase 1 / Phase 2 (10)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (7)
Trial Type
Advanced (40)
Haem (3)
Radonc (3)
Curative (2)
Cancer Therapy Class
PD-1/PD-L1
25%
PD-1
19%
EGFR
13%
KRAS
10%
AR
10%
androgen axis
10%
PD-L1
8%
oestrogen axis
8%
VEGF
8%
Bcl2
6%
VEGFA
6%
BTK
6%
CYP17A1
6%
PSMA
6%
ERBB2
4%
MET
4%
RET
4%
CDK4
4%
ER
4%
B7H4
4%
CCR8
4%
LHRH
4%
ERBB3
4%
AXL
2%
CTLA4
2%
HIF2a
2%
KIT
2%
ROS1
2%
VEGFR
2%
VEGFR2
2%
DNA-dependent protein kinase
2%
CDK2
2%
CDK4 selective
2%
FR-alpha
2%
DLL3
2%
PARG
2%
STEAP1
2%
CLDN6
2%
HRAS G12C
2%
NRAS G12C
2%
FGFR2
2%
FGFR2b
2%
TF
2%
CDH17
2%
CDK6
2%
PARP
2%
PARP1-selective
2%
BRAF
2%
CRAF
2%
MEK
2%
RAF
2%
CD47
2%
VISTA
2%
MUC18
2%
CD93
2%
gp100
2%
CD44v9
2%
CLDN18.2
2%
WEE1
2%
sodium-potassium ATPase
2%
MNK
2%
Facility
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (48)
2109 - North Ryde - Macquarie University Hospital (13)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (12)
3000 - Melbourne - Peter MacCallum Cancer Centre (10)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (9)
3004 - Melbourne, Southbank - Alfred Health (8)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (8)
2065 - St Leonards - GenesisCare North Shore Private Hospital (7)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (7)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
6009 - Nedlands - Linear Clinical Research (6)
2031 - Randwick - Scientia Clinical Research Ltd (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
6150 - Murdoch - Fiona Stanley Hospital (5)
2170 - Liverpool - Liverpool Hospital (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (5)
3199 - Frankston - Peninsula Health Frankston Hospital (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
3168 - Clayton - Monash Medical Centre (4)
6009 - Nedlands - One Clinical Research (4)
4120 - Greenslopes - Greenslopes Private Hospital (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
5042 - Bedford Park - Flinders Medical Centre (3)
4217 - Benowa - Pindara Private Hospital (3)
2076 - Wahroonga - Sydney Adventist Hospital (3)
2605 - Garran - The Canberra Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2640 - Albury - Albury Wodonga Regional Cancer Centre (2)
2139 - Concord - Concord Repatriation General Hospital (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
3066 - Epping - Northern Hospital (2)
3630 - Shepparton - Goulburn Valley Health (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
5000 - Adelaide - Cancer Research SA (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
3677 - Wangaratta - Northeast Health Wangaratta (2)
2500 - Wollongong - Wollongong Hospital (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
4029 - Herston - Metro North Hospital and Health Service (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
6168 - Cooloongup - Rockingham Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4812 - Townsville - Townsville University Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3011 - Footscray - Footscray Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Respiratory tract cancer
Thoracic cancer
Urogenital cancer
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Non-small cell lung cancer
Male genital cancers
Prostate cancer
Colorectal adenocarcinoma
Gynaecological cancer
Carcinoma
B-cell malignancy
Chronic lymphocytic leukaemia
Haematological malignancy
Leukaemia
Lymphoid leukaemia
Mature B-cell malignancy
Ovarian cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Clear cell renal cell carcinoma
Kidney cancer
Prostate adenocarcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Primary fallopian tube serous carcinoma
B-cell lymphoma
Lymphoma
Non-Hodgkin's lymphoma
Small lymphocytic lymphoma
Exocrine pancreatic cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Breast cancer
Melanoma
Mesothelioma
Neuroendocrine tumour
Pleural mesothelioma
Sarcoma
Sarcoma, synovial-like
Synovial sarcoma
Castrate-resistant prostate cancer
Castrate-sensitive prostate cancer
Endometrial cancer
Central nervous system cancer
Glioma
Neurological cancer
Squamous non-small-cell lung cancer
Breast adenocarcinoma
Cervical cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
HPV-related cancer
HPV16-positive cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Oesophageal cancer
Triple-negative breast cancer
Urothelial carcinoma
Viral-related cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy